Lana Pine

Secondary endpoints, including safety, efficacy, immunogenicity, and pharmacokinetics, were highly similar between infliximab and biosimilar CMAB008.

The patient-specific definition of gout remission included minimal symptoms, the absence of dietary restrictions, and management strategies to maintain remission.

Pharmacokinetic parameters and bioequivalence were comparable among patients receiving reference tocilizumab and its proposed biosimilar, HS628.

Fibromyalgia symptoms were reduced at both 4 and 12 weeks in patients receiving tocilizumab treatment.

The analysis suggested a causal relationship between increased tea intake and overall reduced risk of gout in all 3 gout datasets.

A significantly higher number of total outpatient clinic visits was observed in patients with fibromyalgia compared to controls.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

A cross-sectional analysis showed the reliability and repeatability of the Polish version of the Fibromyalgia Impact Questionnaire were "very good."

The empagliflozin reference drug and its biosimilar (CKD-370) demonstrated bioequivalence, and both treatments were well-tolerated among patients.

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

The biosimilar month in review highlights the July 1 launch of 7 adalimumab (Humira) biosimilars in the US and the cost-saving potential of increased biosimilar availability.

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

At the 48-hour mark, the mean difference between high-dose VX-548 and placebo was 37.8 in the abdominoplasty group and 36.8 in the bunionectomy group, thus demonstrating the drug's pain relief potential.

Albert Roy, president of the Lupus Research Alliance, elaborates on recent initiatives designed to address the underrepresentation of minorities in lupus research.

Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.

Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.

The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).

Common themes among patients and parents included a need to accurately assess pain and offer non-pharmacological options for pain management.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

Most (73%) patients surveyed expressed they sought to completely stop or never start using opioids for their chronic pain.

All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases when compared with controls.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

Stephen Pagnotta, executive director and Biosimilar commercial lead at Boehringer Ingelheim, discusses the significance of the US launch of biosimilar adalimumab-adbm and its interchangeable designation.

The estimated total savings was over €243 million for TNF, with over €166 million ascribed to reductions in treatment costs for rheumatic diseases.

At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.

The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.

Patients who completed the survey were significantly more likely to achieve 12-month persistence on adalimumab biosimilar SB5 when compared with non-respondents.

Pediatric rheumatologists were most likely to postpone the decision to withdraw biologic therapy when the patient and/or parents expressed a preference for continuation.

The campaign was inspired by the findings of a global survey conducted with healthcare providers about organ damage in lupus patients.

At the 12-month mark, response rate in patients with uncontrolled gout was significantly higher in those treated with pegloticase and concomitant methotrexate when compared with placebo.